Percheron Therapeutics Limited has released a press release.
First Patient Dosed in ATL1102 Phase IIb DMD Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Chief Executive Officer and Managing Director Appointment
- PIIb DMD trial approved in Bulgaria- UK, Australia advancing
- Dosing commenced in the ATL1102 toxicology study
- Receipt of R&D Tax Incentive Payment
- First approval for ATL1102 Phase IIb DMD clinical trial
Later from Percheron Therapeutics
- MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK
- Institutional Placement and proposed Share Purchase Plan SPP
- Quarterly Activities Report
- Intention to launch Share Purchase Plan
- Positive new DMD Combination Therapy Data in mdx mice
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics